The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to facilitate the conduct of decentralised clinical trials (DCTs) while safeguarding the rights and well-being of participants as well as the robustness and reliability of the data collected.
Patrycja Buczak-Kula
Clinical Trials in the European Union (ACT EU).
https://www.ema.europa.eu/en/news/facilitating-decentralised-clinical-trials-eu
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…
Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While…
Copyright @ 2025 Axcellant